Possible role of the cholinergic system and disease models

  • M. Weinstock


Memory impairment associated with the loss of cortical cholinergic neurons in AD has stimulated the development of animal models based on blockade or destruction of these systems. Strategies include mechanical lesions, local injection of excitotoxic amino acids or ethylcholine aziridinium (AF 64A), which disrupt reference and working memory in rats, but lack specificity for cholinergic systems. Other models involving, reduction in cerebral blood flow and interference with oxidative metabolism of glucose, mimic those found in AD, and also interfere with working and long-term memory in the rat. Memory impairments can be reversed by acetylcholinesterase inhibitors and cholinergic agonists but beneficial effects of these agents in AD patients are small and inconsistent. This may be partly due to unfavorable pharmacokinetics and dose-limiting side effects of existing drugs. Newer, brain specific acetylcholinesterase inhibitors and Ml muscarinic agonists with a lower incidence of unwanted effects are currently being evaluated.


Basal Forebrain Cholinergic System AChE Inhibitor Cholinergic Transmission Nucleus Basalis Magnocellularis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bennett MC, Diamond DM, Parker WD, Stryker SL, Rose GM (1992) Inhibition of cytochrome oxidase impairs learning and hippocampal plasticity: a novel animal model of Alzheimer’s disease. In: Meyer EM, et al (eds) Treatment of dementias. Plenum Press, New YorkGoogle Scholar
  2. Bevan P (1984) Effect of muscarinic ligands on the electrical activity recorded from the hippocampus: a quantitative approach. Br J Pharmacol 82: 431–440PubMedGoogle Scholar
  3. Chalmers DT, Dewar D, Graham DI, Brooks DN, McCulloch J (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci USA 87: 1352–1356PubMedCrossRefGoogle Scholar
  4. Christie JE, Shering A, Fergusen J, Glen AIM (1981) Physostigmine and arecholine: efffects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138: 46–50PubMedCrossRefGoogle Scholar
  5. Cummings JL, Gorman DG, Shapira J (1993) Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry 33: 536–541PubMedCrossRefGoogle Scholar
  6. Davis KL, Thal L, Gamzu E, Davis CS, Woolson RF, Gracon SI, et al (1992) A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer’s disease. N Engl J Med 327: 1253–1259PubMedCrossRefGoogle Scholar
  7. Dekker AJAM, Connor DJ, Thal LJ (1991) The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 15: 299–317PubMedCrossRefGoogle Scholar
  8. Divac I (1975) Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, and olfactory bulb. Review of some functional correlates. Brain Res 93: 385–398PubMedCrossRefGoogle Scholar
  9. Dubois B, Mayo W, Agid Y, Le Moal M, Simon H (1985) Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat. Brain Res 338: 249–258PubMedCrossRefGoogle Scholar
  10. Dunnett SB, Everitt BJ, Robbins TW (1991) The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. TINS 14: 494–501PubMedGoogle Scholar
  11. Enz A, Boddeke H, Gray J, Spiegel R (1991) Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally-selective acetylcholinesterase inhibitor. Ann NY Acad Sci 640: 272–275PubMedGoogle Scholar
  12. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog Brain Res 98: 431–438PubMedCrossRefGoogle Scholar
  13. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: investigative and therapeutic perspectives. J Neurochem 60: 1589–1604PubMedCrossRefGoogle Scholar
  14. Gauthier S, Gauthier L (1993) What we have learned from the THA trials to facilitate testing of new AChE inhibitors. Prog Brain Res 98: 427–429PubMedCrossRefGoogle Scholar
  15. Holsboer-Trachsler E, Hatsinger M, Syohler R, Hemmeter U, Gray J, Muller J, et al (1993) Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 8: 87–92PubMedGoogle Scholar
  16. Hoyer S (1992) Intermediary metabolism disturbance in AD/SDAT and its relation to molecular events. Prog Neuropsychopharmacol Biol Psychiatry 17: 199–228CrossRefGoogle Scholar
  17. Iversen LL (1993) Approaches to cholinergic therapy in Alzheimer’s disease. Prog Brain Res 98: 423–426PubMedCrossRefGoogle Scholar
  18. Jerrard LE, Kant GJ, Meyerhoff JL, Levy A (1984) Behavioral and neurochemical effects of intraventricular AF64A administration in rats. Pharmacol Biochem Behav 21: 273–280CrossRefGoogle Scholar
  19. Kakihana M, Yamazaki N, Nagaoka A (1984) Effects of idebenone (CV-2619) on the concentrations of acetylcholine and choline in various brain regions of rats with cerebral ischemia. Jpn J Pharmacol 36: 357–363PubMedCrossRefGoogle Scholar
  20. Kasa P, Szerdahelyi P, Fisher A, Hanin I (1986) Histochemical and electronmicroscopic study of the brain of the AF64A-treated rat. In: Fisher A, Hanin I, Lachman C (eds) Alzheimer’s and Parkinson’s diseases: strategies for research and development. Plenum Press, New YorkGoogle Scholar
  21. Khachaturian ZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42: 1097–1105PubMedGoogle Scholar
  22. Lavretsky EP, Jarvik LF (1992) A group of potassium-channel blockers — acetylcholine releasers: new potentials for Alzheimer’s disease? J Clin Psychopharmacol 12: 110–118PubMedCrossRefGoogle Scholar
  23. Lines CR, Ambrose JH, Heald A, Traub M (1993) A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. Hum Psychopharmacol 8: 271–278CrossRefGoogle Scholar
  24. Linville DG, Giacobini E, Arneric SP (1992) Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow. J Neurosci Res 31: 573–577PubMedCrossRefGoogle Scholar
  25. McKinnley M, Coyle JT, Hedreen JC (1983) Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. J Comp Neurol 217: 103–121CrossRefGoogle Scholar
  26. McNamara RK, Skelton RW (1993) The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 18: 33–49PubMedCrossRefGoogle Scholar
  27. Miyamoto M, Kato J, Narumi S, Nagaoka A (1987) Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. Brain Res 419: 19–31PubMedCrossRefGoogle Scholar
  28. Miyamoto M, Narumi S, Nagaoka A, Coyle JT (1989) Effects of continous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J Pharmacol Exp Ther 248: 825–835PubMedGoogle Scholar
  29. Nabeshima T (1993) Behavioral aspects of cholinergic transmission: role of basal forebrain cholinergic system in learning and memory. Prog Brain Res 98: 405–411PubMedCrossRefGoogle Scholar
  30. Olton DS (1977) Spatial memory. Sci Am 236: 82–98Google Scholar
  31. Paoletti F, Mocali A, Vanucchi A (1992) Acetylcholinesterase in murine erythroleukemia (Friend) cells: evidence for megakaryocyte-like expression and potential growth-regulatory role of enzyme activity. Blood 79: 2873–2879PubMedGoogle Scholar
  32. Perry EK (1986) The cholinergic hypothesis — ten years on. Br Med Bull 42: 63–69PubMedGoogle Scholar
  33. Quirion R, Marbel JC, Robitaille Y, Etienne P, Wood P, Nair NVP, Gauthier S (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neural Sci 13: 503–510Google Scholar
  34. Sandberg K, Sandberg PR, Hanin I, Fisher A, Coyle JT (1984) Cholinergic lesion of the striatum impairs acquisition and retention of a passive avoidance response. Behav Neurosci 98: 162–165PubMedCrossRefGoogle Scholar
  35. Sano M, Bell K, Marder K, Stricks L, Stem Y, Mayeux R (1993) Safety and efficacy of oral physostigmine in the treatment of Alzheimer’s disease. Clin Neuropharmacol 16: 61–69PubMedCrossRefGoogle Scholar
  36. Scremin OU, Allen K, Torres C, Scremin E (1988) Physostigmine enhances blood flow — metabolism ratio in neocortex. Neuropsychopharmacol 1: 297–303Google Scholar
  37. Sherman KA, Kumar V, Ashford JW, Murphy JM, Elble RJ, Smith R, Giacobini E (1987) Effect of oral physostigmine in senile dementia patients: utility of blood Cholinesterase inhibition and neuroendocrine response to define pharmacokinetics and pharmacodynamics. In: Strong R, Woods WG, Burke WJ (eds) Central nervous system disorders of aging: strategies for intervention and research (aging). Raven Press, New YorkGoogle Scholar
  38. Siek GC, Kats LS, Fishman EB, Korosi TS, Maquis JK (1990) Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 27: 573–580PubMedCrossRefGoogle Scholar
  39. Sims NR, Bowen DM, Allen S J, Smith CCT, Neary D, Thomas DJ, Davison AN (1983a) Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 40:503–509PubMedCrossRefGoogle Scholar
  40. Sims NR, Bowen DM, Neary D, Davison AN (1983b) Metabolic processes in Alzheimer’s disease: adenine nucleotide content and production of 14CO2 from [U-14C] glucose in vitro in human neocortex. J Neurochem 41: 1329–1334PubMedCrossRefGoogle Scholar
  41. Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R (1993) Safety and efficacy of oral physostigmine in the treatment of Alzheimer’s disease. Clin Neuropharmacol 16: 61–69PubMedCrossRefGoogle Scholar
  42. Stern Y, Sano M, Mayeux R (1987) Effects of oral physostigmine in Alzheimer’s disease. Ann Neurol 22: 306–310PubMedCrossRefGoogle Scholar
  43. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydro-aminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245PubMedCrossRefGoogle Scholar
  44. Weinstock M, Razin M, Chorev M, Tashma Z (1986) Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer’s disease. In: Fisher A, Hanin I, Lachman C (eds) Advances in behavioral biology. Plenum Press, New YorkGoogle Scholar
  45. Weinstock M, Razin M, Chorev M, Enz A (1994) Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm [Suppl] 43: 307–309Google Scholar
  46. Yamamoto T, Ohno M, Kitajima I, Yatsugi SI, Ueki S (1993) Ameliorative effects of the centrally active Cholinesterase inhibitor, NIK-247, on impairment of working memory in rats. Physiol Behav 53: 5–10PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • M. Weinstock
    • 1
  1. 1.Department of Pharmacology, School of PharmacyHebrew University Hadassah Medical CentreJerusalemIsrael

Personalised recommendations